Regenerative Medicine · asia
Delivering Neural Progenitor Cells Into the Injured Spinal Cord: First-in-Human Trial Clears Initial Safety Threshold
Four patients with complete cervical spinal cord injuries showed no tumors or serious graft-related events during two to four years of follow-up after transplantation of iPSC-derived neural cells; two had marked improvements in neurological function grade, but this small, uncontrolled trial cannot yet demonstrate efficacy.
Once the spinal cord is severely damaged, medical care can stabilize the spine, reduce subsequent injury, and support rehabilitation, but it is difficult to rebuild severed neural circuits. A first-in-human study published in *Nature Medicine* now shows that neural stem and progenitor cells made from induced pluripotent stem cells (iPSCs) can be transplanted directly into the injured human spinal cord, clearing an initial safety threshold during follow-up lasting up to four years.
This phase 1 trial enrolled four men aged 26 to 66, all with subacute, complete cervical spinal cord injuries caused by trauma, at levels ranging from C4 to C6. Between 14 and 28 days after injury, the research team injected 2 million cells into the center of the lesion under ultrasound guidance. The patients also received short-term immunosuppression with tacrolimus for six months, followed by gradual dose reduction and discontinuation in the ninth month.
All four participants completed the 52-week interventional study and subsequently entered long-term observation. At the time of the paper’s analysis, individual follow-up ranged from two to four years. Imaging found no tumors, abnormal cell proliferation, or other graft-related changes, and no serious adverse events were judged to have originated from the transplanted cells. The study recorded procedure-related cerebrospinal fluid leakage and increased upper respiratory tract secretions; immunosuppressive treatment was associated with mild to moderate events including hypomagnesemia and urinary tract infections, showing that “the cells themselves are safe” does not mean the entire treatment is without burden.
The functional results produced a more notable signal. At 52 weeks after transplantation, the four participants’ standardized motor scores had increased by a median of 13 points from baseline, with a range of 10 to 40 points. Two participants improved on the American Spinal Injury Association Impairment Scale (AIS) from the most severe grade, A, to grades C and D, respectively, indicating recovery of varying degrees of sensation and voluntary movement below the level of injury. These improvements were largely maintained after one year, with no further significant changes during long-term follow-up.
The research team also used 52 patients selected from a Japanese spinal cord injury database as a historical reference. At 52 weeks, the transplantation group had numerically higher motor scores and a higher proportion of participants improving to AIS grade C or above than the historical group. However, the four-person trial involved neither random assignment nor a concurrent control group, and patient selection, rehabilitation conditions, and preserved spinal cord structures could all affect recovery. Subacute spinal cord injury can also show spontaneous improvement of varying magnitude, so the functional gains cannot currently be attributed to cell transplantation.
What these findings truly establish is that quality-controlled iPSC-derived neural cells can be manufactured, stored, and delivered into the human spinal cord, without evidence of medium-term tumor risk under short-term immunosuppression. The study could not directly confirm whether the transplanted cells survived, differentiated, and integrated into the host neural circuits; invasive injection, the adverse effects of immunosuppression, and long-term abnormal proliferation also remain questions that subsequent trials must address. The observational study of the same group of patients is scheduled to continue through 2035, while whether the treatment is effective must still be verified in larger clinical trials with concurrent controls.